Though enzalutamide, by invoking direct androgen receptor inhibition, and abiraterone, by blocking androgen biosynthesis, have early biochemical patterns which converge, especially during the hormone sensitive phase, when tumor androgen dependence prevails. The gene discussed is AR; the disease is neoplasm.